Modulation of N-methyl-D-aspartate receptors in the brain by protein phosphorylation may play a central role in the regulation of synaptic plasticity. To examine the phosphorylation of the NR1 subunit of N-methyl-Daspartate receptors in situ, we have generated several polyclonal antibodies that recognize the NR1 subunit only when specific serine residues are phosphorylated. Using these antibodies, we demonstrate that protein kinase C (PKC) phosphorylates serine residues 890 and 896 and cAMP-dependent protein kinase (PKA) phosphorylates serine residue 897 of the NR1 subunit. Activation of PKC and PKA together lead to the simultaneous phosphorylation of neighboring serine residues 896 and 897. Phosphorylation of serine 890 by PKC results in the dispersion of surface-associated clusters of the NR1 subunit expressed in fibroblasts, while phosphorylation of serine 896 and 897 has no effect on the subcellular distribution of NR1. The PKC-induced redistribution of the NR1 subunit in cells occurs within minutes of serine 890 phosphorylation and reverses upon dephosphorylation. These results demonstrate that PKA and PKC phosphorylate distinct residues within a small region of the NR1 subunit and differentially affect the subcellular distribution of the NR1 subunit.Ionotropic glutamate receptors mediate most rapid excitatory transmission in the central nervous system and play important roles in synaptic plasticity, neuronal development, and neurological disorders (1-5). Glutamate receptors have been divided into NMDA 1 (N-methyl-D-aspartate) and non-NMDA (kainate or AMPA) receptors based on their pharmacological and physiological properties (1, 2). Non-NMDA glutamate receptors activate and desensitize rapidly and mediate excitatory synaptic transmission. NMDA receptors are more slowly activated and desensitized and have a high Ca 2ϩ permeability and a voltage-dependent Mg 2ϩ block, two properties thought to underlie use-dependent synaptic plasticity in the brain (1-3). Molecular cloning studies have recently identified the genes encoding subunits for the NMDA and non-NMDA receptors (1, 2). NMDA receptors consist of two families of homologous subunits, the NR1 and NR2A-D subunits (6 -9), and are thought to be pentameric or tetrameric complexes of the NR1 subunit with one or more of the NR2 subunits (10, 11). The differential expression of NR2 subunits in the various regions of the brain may account for the diversity of NMDA receptor subtypes (1). In addition, the NR1 subunit is highly alternatively spliced giving rise to at least seven forms of NR1 (NR1A-G) increasing the potential diversity of NMDA receptors in the brain (12-14).Protein phosphorylation has been recognized as a major mechanism for the regulation of glutamate receptor function (15). NMDA receptors appear to be regulated by a number of protein kinases and phosphatases. Activation of protein kinase C (PKC) by phorbol esters have been demonstrated to activate (16,17) or depress (18, 19) neuronal NMDA receptors. In addition, intracellular perfusion of purified ...

The NMDA (N-methyl D-aspartate) receptors in the brain play a critical role in synaptic plasticity, synaptogenesis and excitotoxicity. Molecular cloning has demonstrated that NMDA receptors consist of several homologous subunits (NMDAR1, 2A-2D). A variety of studies have suggested that protein phosphorylation of NMDA receptors may regulate their function and play a role in many forms of synaptic plasticity such as long-term potentiation. We have examined the phosphorylation of the NMDA receptor subunit NMDAR1 (NR1) by protein kinase C (PKC) in cells transiently expressing recombinant NR1 and in primary cultures of cortical neurons. PKC phosphorylation occurs on several distinct sites on the NR1 subunit. Most of these sites are contained within a single alternatively spliced exon in the C-terminal domain, which has previously been proposed to be on the extracellular side of the membrane. These results demonstrate that alternative splicing of the NR1 messenger RNA regulates its phosphorylation by PKC, and that mRNA splicing is a novel mechanism for regulating the sensitivity of glutamate receptors to protein phosphorylation. These results also provide evidence that the C-terminal domain of the NR1 protein is located intracellularly, suggesting that the proposed transmembrane topology model for glutamate receptors may be incorrect.

NMDA (N-methyl-D-aspartate) receptors are selectively localized at the postsynaptic membrane of excitatory synapses in the mammalian brain. The molecular mechanisms underlying this localization were investigated by expressing the NR1 subunit of the NMDA receptor in fibroblasts. NR1 splice variants containing the first COOH-terminal exon cassette (NR1A and NR1D) were located in discrete, receptor-rich domains associated with the plasma membrane. NR1 splice variants lacking this exon cassette (NR1C and NR1E) were distributed throughout the cell, with large amounts of NR1 protein present in the cell interior. Insertion of this exon cassette into the COOH-terminus of the GluR1 AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor was sufficient to cause GluR1 to be localized to discrete, receptor-rich domains. Furthermore, protein kinase C phosphorylation of specific serines within this exon disrupted the receptor-rich domains. These results demonstrate that amino acid sequences contained within the NR1 molecule serve to localize this receptor subunit to discrete membrane domains in a manner that is regulated by alternative splicing and protein phosphorylation.

Background Diagnosis of significant coronary artery disease (CAD) in at risk patients can be challenging, typically including non-invasive imaging modalities and ultimately the gold standard of coronary angiography. Previous studies suggested that peripheral blood gene expression can reflect the presence of CAD. Objective To validate a previously developed 23-gene expression-based classifier for diagnosis of obstructive CAD in non-diabetic patients. Design Multi-center prospective trial with blood samples drawn prior to coronary angiography. Setting Thirty-nine US centers. Patients An independent validation cohort of 526 non-diabetic patients clinically-indicated for coronary angiography Intervention None. Measurements Receiver-operator characteristics (ROC) analysis of classifier score measured by real-time polymerase chain reaction (RT-PCR), additivity to clinical factors, and reclassification of patient disease likelihood vs disease status defined by quantitative coronary angiography (QCA). Obstructive CAD defined as ≥50% stenosis in ≥1 major coronary artery by QCA. Results The overall ROC curve area (AUC) was 0.70 ±0.02, (p<0.001); the classifier added to clinical variables (Diamond-Forrester method) (AUC 0.72 with classifier vs 0.66 without, p = 0.003). Net reclassification was improved by the classifier over Diamond-Forrester and an expanded clinical model (both p<0.001). At a score threshold corresponding to 20% obstructive CAD likelihood (14.75), the sensitivity and specificity were 85% and 43%, yielding NPV of 83% and PPV 46%, with 33% of patient scores below this threshold. Limitations The study excluded patients with chronic inflammatory disorders, elevated white blood counts or cardiac protein markers, and diabetes. Conclusions This non-invasive whole blood test, based on gene expression and demographics, may be useful for assessment of obstructive CAD in non-diabetic patients without known CAD. Primary Funding Source CardioDx, Inc.